Inhibiting histone and DNA methylation improves cancer vaccination in an experimental model of melanoma

Immunotherapy has improved the treatment of malignant skin cancer of the melanoma type, yet overall clinical response rates remain low. Combination therapies could be key to meet this cogent medical need. Because epigenetic hallmarks represent promising combination therapy targets, we studied the im...

Descripción completa

Detalles Bibliográficos
Autores: De-Beck, L. (Lien)|||/items/29101c5e-3eaa-4306-8e20-a4290afa3192, Awad, R.M. (Robin Maximilian)|||/items/1087d86e-29ee-4592-a4ab-9eac69d921d7, Basso, V. (Veronica)|||/items/cd7daa55-e25c-45ae-bce7-79b01f7712c2, Casares-Lagar, N. (Noelia)|||/items/32524a9b-f393-47ee-bf77-0737c65e0b7b, De-Ridder, K. (Kirsten)|||/items/19fcf443-dd65-4fe0-8ee8-dd30a6322164, De-Vlaeminck, Y. (Yannick)|||/items/9a5ae9bd-608a-4f8e-a7f1-d663d526aa66, Gnata, A. (Alessandra)|||/items/b4c543c9-21b1-4520-9c1b-f6e02ced54be, Goyvaerts, C. (Cleo)|||/items/74c60779-b765-4223-85ae-e927a5b4f2a2, Lecocq, Q. (Quentin)|||/items/42c2cfb5-c303-4504-8068-d641f030efa0, San-José-Enériz, E. (Edurne)|||/items/1c6714b1-f536-4b57-a755-83eca42e9964, Verhulst, S. (Stefaan)|||/items/ed541fbd-0664-4d30-967f-d481b35924f9, Maes, K. (Ken)|||/items/9af6494a-db92-4001-9073-634cc84ae902, Vanderkerken, K. (Karin)|||/items/afb22f0b-34a8-4e49-84bb-52ad550bf66a, Prosper-Cardoso, F. (Felipe)|||/items/3d1b0b82-06c3-4e63-8280-e903dc4dc0c1, Lasarte-Sagastibelza, J.J. (Juan José)|||/items/e366ad83-3db4-41ec-a9da-ed9159ba5c0c, Mondino, A. (Anna)|||/items/526c1918-c5a1-4858-a84c-20c6d69ff79a, Breckpot, K. (Karine)|||/items/a8a26dbc-ff97-4670-aa0f-fe536be9ff1b, Aguirre-Ena, X. (Xabier)|||/items/2a000d9c-cb5c-4734-a32c-4fef79998c86
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/116517
Acceso en línea:https://hdl.handle.net/10171/116517
Access Level:acceso abierto
Palabra clave:Melanoma
Cancer vaccination
Dendritic cell vaccination
Adoptive T cell therapies
Epigenetic targeted therapy
Histone and DNA methylation/demethylation
Histone methyltransferase G9a
DNA methyltransferase (DNMT)
id ES_05e52c321fa31ad40d82e8cc3ffce178
oai_identifier_str oai:dadun.unav.edu:10171/116517
network_acronym_str ES
network_name_str España
repository_id_str
spelling Inhibiting histone and DNA methylation improves cancer vaccination in an experimental model of melanomaDe-Beck, L. (Lien)|||/items/29101c5e-3eaa-4306-8e20-a4290afa3192Awad, R.M. (Robin Maximilian)|||/items/1087d86e-29ee-4592-a4ab-9eac69d921d7Basso, V. (Veronica)|||/items/cd7daa55-e25c-45ae-bce7-79b01f7712c2Casares-Lagar, N. (Noelia)|||/items/32524a9b-f393-47ee-bf77-0737c65e0b7bDe-Ridder, K. (Kirsten)|||/items/19fcf443-dd65-4fe0-8ee8-dd30a6322164De-Vlaeminck, Y. (Yannick)|||/items/9a5ae9bd-608a-4f8e-a7f1-d663d526aa66Gnata, A. (Alessandra)|||/items/b4c543c9-21b1-4520-9c1b-f6e02ced54beGoyvaerts, C. (Cleo)|||/items/74c60779-b765-4223-85ae-e927a5b4f2a2Lecocq, Q. (Quentin)|||/items/42c2cfb5-c303-4504-8068-d641f030efa0San-José-Enériz, E. (Edurne)|||/items/1c6714b1-f536-4b57-a755-83eca42e9964Verhulst, S. (Stefaan)|||/items/ed541fbd-0664-4d30-967f-d481b35924f9Maes, K. (Ken)|||/items/9af6494a-db92-4001-9073-634cc84ae902Vanderkerken, K. (Karin)|||/items/afb22f0b-34a8-4e49-84bb-52ad550bf66aProsper-Cardoso, F. (Felipe)|||/items/3d1b0b82-06c3-4e63-8280-e903dc4dc0c1Lasarte-Sagastibelza, J.J. (Juan José)|||/items/e366ad83-3db4-41ec-a9da-ed9159ba5c0cMondino, A. (Anna)|||/items/526c1918-c5a1-4858-a84c-20c6d69ff79aBreckpot, K. (Karine)|||/items/a8a26dbc-ff97-4670-aa0f-fe536be9ff1bAguirre-Ena, X. (Xabier)|||/items/2a000d9c-cb5c-4734-a32c-4fef79998c86MelanomaCancer vaccinationDendritic cell vaccinationAdoptive T cell therapiesEpigenetic targeted therapyHistone and DNA methylation/demethylationHistone methyltransferase G9aDNA methyltransferase (DNMT)Immunotherapy has improved the treatment of malignant skin cancer of the melanoma type, yet overall clinical response rates remain low. Combination therapies could be key to meet this cogent medical need. Because epigenetic hallmarks represent promising combination therapy targets, we studied the immunogenic potential of a dual inhibitor of histone methyltransferase G9a and DNA methyltransferases (DNMTs) in the preclinical B16-OVA melanoma model. Making use of tumor transcriptomic and functional analyses, methylation-targeted epigenetic reprogramming was shown to induce tumor cell cycle arrest and apoptosis in vitro coinciding with transient tumor growth delay and an IFN-I response in immune-competent mice. In consideration of a potential impact on immune cells, the drug was shown not to interfere with dendritic cell maturation or T-cell activation in vitro. Notably, the drug promoted dendritic cell and, to a lesser extent, T-cell infiltration in vivo, yet failed to sensitize tumor cells to programmed cell death-1 inhibition. Instead, it increased therapeutic efficacy of TCR-redirected T cell and dendritic cell vaccination, jointly increasing overall survival of B16-OVA tumor-bearing mice. The reported data confirm the prospect of methylation-targeted epigenetic reprogramming in melanoma and sustain dual G9a and DNMT inhibition as a strategy to tip the cancer-immune set-point towards responsiveness to active and adoptive vaccination against melanoma.Frontiers Media S.A.Dadun. Depósito Académico Digital Universidad de Navarra20222022-01-0120222022-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/116517reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/1165172026-06-21T12:47:57Z
dc.title.none.fl_str_mv Inhibiting histone and DNA methylation improves cancer vaccination in an experimental model of melanoma
title Inhibiting histone and DNA methylation improves cancer vaccination in an experimental model of melanoma
spellingShingle Inhibiting histone and DNA methylation improves cancer vaccination in an experimental model of melanoma
De-Beck, L. (Lien)|||/items/29101c5e-3eaa-4306-8e20-a4290afa3192
Melanoma
Cancer vaccination
Dendritic cell vaccination
Adoptive T cell therapies
Epigenetic targeted therapy
Histone and DNA methylation/demethylation
Histone methyltransferase G9a
DNA methyltransferase (DNMT)
title_short Inhibiting histone and DNA methylation improves cancer vaccination in an experimental model of melanoma
title_full Inhibiting histone and DNA methylation improves cancer vaccination in an experimental model of melanoma
title_fullStr Inhibiting histone and DNA methylation improves cancer vaccination in an experimental model of melanoma
title_full_unstemmed Inhibiting histone and DNA methylation improves cancer vaccination in an experimental model of melanoma
title_sort Inhibiting histone and DNA methylation improves cancer vaccination in an experimental model of melanoma
dc.creator.none.fl_str_mv De-Beck, L. (Lien)|||/items/29101c5e-3eaa-4306-8e20-a4290afa3192
Awad, R.M. (Robin Maximilian)|||/items/1087d86e-29ee-4592-a4ab-9eac69d921d7
Basso, V. (Veronica)|||/items/cd7daa55-e25c-45ae-bce7-79b01f7712c2
Casares-Lagar, N. (Noelia)|||/items/32524a9b-f393-47ee-bf77-0737c65e0b7b
De-Ridder, K. (Kirsten)|||/items/19fcf443-dd65-4fe0-8ee8-dd30a6322164
De-Vlaeminck, Y. (Yannick)|||/items/9a5ae9bd-608a-4f8e-a7f1-d663d526aa66
Gnata, A. (Alessandra)|||/items/b4c543c9-21b1-4520-9c1b-f6e02ced54be
Goyvaerts, C. (Cleo)|||/items/74c60779-b765-4223-85ae-e927a5b4f2a2
Lecocq, Q. (Quentin)|||/items/42c2cfb5-c303-4504-8068-d641f030efa0
San-José-Enériz, E. (Edurne)|||/items/1c6714b1-f536-4b57-a755-83eca42e9964
Verhulst, S. (Stefaan)|||/items/ed541fbd-0664-4d30-967f-d481b35924f9
Maes, K. (Ken)|||/items/9af6494a-db92-4001-9073-634cc84ae902
Vanderkerken, K. (Karin)|||/items/afb22f0b-34a8-4e49-84bb-52ad550bf66a
Prosper-Cardoso, F. (Felipe)|||/items/3d1b0b82-06c3-4e63-8280-e903dc4dc0c1
Lasarte-Sagastibelza, J.J. (Juan José)|||/items/e366ad83-3db4-41ec-a9da-ed9159ba5c0c
Mondino, A. (Anna)|||/items/526c1918-c5a1-4858-a84c-20c6d69ff79a
Breckpot, K. (Karine)|||/items/a8a26dbc-ff97-4670-aa0f-fe536be9ff1b
Aguirre-Ena, X. (Xabier)|||/items/2a000d9c-cb5c-4734-a32c-4fef79998c86
author De-Beck, L. (Lien)|||/items/29101c5e-3eaa-4306-8e20-a4290afa3192
author_facet De-Beck, L. (Lien)|||/items/29101c5e-3eaa-4306-8e20-a4290afa3192
Awad, R.M. (Robin Maximilian)|||/items/1087d86e-29ee-4592-a4ab-9eac69d921d7
Basso, V. (Veronica)|||/items/cd7daa55-e25c-45ae-bce7-79b01f7712c2
Casares-Lagar, N. (Noelia)|||/items/32524a9b-f393-47ee-bf77-0737c65e0b7b
De-Ridder, K. (Kirsten)|||/items/19fcf443-dd65-4fe0-8ee8-dd30a6322164
De-Vlaeminck, Y. (Yannick)|||/items/9a5ae9bd-608a-4f8e-a7f1-d663d526aa66
Gnata, A. (Alessandra)|||/items/b4c543c9-21b1-4520-9c1b-f6e02ced54be
Goyvaerts, C. (Cleo)|||/items/74c60779-b765-4223-85ae-e927a5b4f2a2
Lecocq, Q. (Quentin)|||/items/42c2cfb5-c303-4504-8068-d641f030efa0
San-José-Enériz, E. (Edurne)|||/items/1c6714b1-f536-4b57-a755-83eca42e9964
Verhulst, S. (Stefaan)|||/items/ed541fbd-0664-4d30-967f-d481b35924f9
Maes, K. (Ken)|||/items/9af6494a-db92-4001-9073-634cc84ae902
Vanderkerken, K. (Karin)|||/items/afb22f0b-34a8-4e49-84bb-52ad550bf66a
Prosper-Cardoso, F. (Felipe)|||/items/3d1b0b82-06c3-4e63-8280-e903dc4dc0c1
Lasarte-Sagastibelza, J.J. (Juan José)|||/items/e366ad83-3db4-41ec-a9da-ed9159ba5c0c
Mondino, A. (Anna)|||/items/526c1918-c5a1-4858-a84c-20c6d69ff79a
Breckpot, K. (Karine)|||/items/a8a26dbc-ff97-4670-aa0f-fe536be9ff1b
Aguirre-Ena, X. (Xabier)|||/items/2a000d9c-cb5c-4734-a32c-4fef79998c86
author_role author
author2 Awad, R.M. (Robin Maximilian)|||/items/1087d86e-29ee-4592-a4ab-9eac69d921d7
Basso, V. (Veronica)|||/items/cd7daa55-e25c-45ae-bce7-79b01f7712c2
Casares-Lagar, N. (Noelia)|||/items/32524a9b-f393-47ee-bf77-0737c65e0b7b
De-Ridder, K. (Kirsten)|||/items/19fcf443-dd65-4fe0-8ee8-dd30a6322164
De-Vlaeminck, Y. (Yannick)|||/items/9a5ae9bd-608a-4f8e-a7f1-d663d526aa66
Gnata, A. (Alessandra)|||/items/b4c543c9-21b1-4520-9c1b-f6e02ced54be
Goyvaerts, C. (Cleo)|||/items/74c60779-b765-4223-85ae-e927a5b4f2a2
Lecocq, Q. (Quentin)|||/items/42c2cfb5-c303-4504-8068-d641f030efa0
San-José-Enériz, E. (Edurne)|||/items/1c6714b1-f536-4b57-a755-83eca42e9964
Verhulst, S. (Stefaan)|||/items/ed541fbd-0664-4d30-967f-d481b35924f9
Maes, K. (Ken)|||/items/9af6494a-db92-4001-9073-634cc84ae902
Vanderkerken, K. (Karin)|||/items/afb22f0b-34a8-4e49-84bb-52ad550bf66a
Prosper-Cardoso, F. (Felipe)|||/items/3d1b0b82-06c3-4e63-8280-e903dc4dc0c1
Lasarte-Sagastibelza, J.J. (Juan José)|||/items/e366ad83-3db4-41ec-a9da-ed9159ba5c0c
Mondino, A. (Anna)|||/items/526c1918-c5a1-4858-a84c-20c6d69ff79a
Breckpot, K. (Karine)|||/items/a8a26dbc-ff97-4670-aa0f-fe536be9ff1b
Aguirre-Ena, X. (Xabier)|||/items/2a000d9c-cb5c-4734-a32c-4fef79998c86
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv Melanoma
Cancer vaccination
Dendritic cell vaccination
Adoptive T cell therapies
Epigenetic targeted therapy
Histone and DNA methylation/demethylation
Histone methyltransferase G9a
DNA methyltransferase (DNMT)
topic Melanoma
Cancer vaccination
Dendritic cell vaccination
Adoptive T cell therapies
Epigenetic targeted therapy
Histone and DNA methylation/demethylation
Histone methyltransferase G9a
DNA methyltransferase (DNMT)
description Immunotherapy has improved the treatment of malignant skin cancer of the melanoma type, yet overall clinical response rates remain low. Combination therapies could be key to meet this cogent medical need. Because epigenetic hallmarks represent promising combination therapy targets, we studied the immunogenic potential of a dual inhibitor of histone methyltransferase G9a and DNA methyltransferases (DNMTs) in the preclinical B16-OVA melanoma model. Making use of tumor transcriptomic and functional analyses, methylation-targeted epigenetic reprogramming was shown to induce tumor cell cycle arrest and apoptosis in vitro coinciding with transient tumor growth delay and an IFN-I response in immune-competent mice. In consideration of a potential impact on immune cells, the drug was shown not to interfere with dendritic cell maturation or T-cell activation in vitro. Notably, the drug promoted dendritic cell and, to a lesser extent, T-cell infiltration in vivo, yet failed to sensitize tumor cells to programmed cell death-1 inhibition. Instead, it increased therapeutic efficacy of TCR-redirected T cell and dendritic cell vaccination, jointly increasing overall survival of B16-OVA tumor-bearing mice. The reported data confirm the prospect of methylation-targeted epigenetic reprogramming in melanoma and sustain dual G9a and DNMT inhibition as a strategy to tip the cancer-immune set-point towards responsiveness to active and adoptive vaccination against melanoma.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-01-01
2022
2022-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10171/116517
url https://hdl.handle.net/10171/116517
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Frontiers Media S.A.
publisher.none.fl_str_mv Frontiers Media S.A.
dc.source.none.fl_str_mv reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra
instname:Universidad de Navarra
instname_str Universidad de Navarra
reponame_str Dadun. Depósito Académico Digital de la Universidad de Navarra
collection Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402884063363072
score 15.812429